Peer-Reviewed Publications

As one of the well-recognized service providers, Creative Biolabs is dedicated to assisting our clients with the most satisfactory single domain antibody related services. Our well-trained full-time scientists can work closely with our research partners and customers for the customized proposal to meet the special project requirements in the quality and timeline.

One-stop discovery platforms from Creative Biolabs enable the novel single domain antibody discovery as research tool, therapeutic candidate, or diagnostic reagent. From the target identification to the final IND-enabling, we have the capability to enable you to free up your time for core work and project. Furthermore, the subsequent sdAb development and characterization services can further meet the diverse needs of our customers. A long list of articles has been published in peer-reviewed journals and a lot of patents have been approved or in process which cited products or services from Creative Biolabs. This document filed some selected articles to provide an overview about how we can be involved in your academic or industrial project.

For your convenience, we have grouped these patents & articles into the following categories:

• SECTION 1: One-Stop sdAb Development Services
• SECTION 2: Single Domain Antibody Products

Creative Biolabs has integrated the expertise with cutting-edge technologies and extended them to establish a series of one-stop procedures, which can contribute to the development of novel single domain antibodies.

• Singh, Sunanda, et al. "Suppression of Breast Cancer Cell Proliferation by Selective Single-Domain Antibody for Intracellular STAT3." Breast cancer: basic and clinical research 12 (2018): 1178223417750858.

• This paper mentioned Creative Biolabs provided VHHs against STAT3, as well as the second PCR product from STAT3 V_HH gene and pCDisplay-3M phagemid.

• Mashalidis, Ellene H., et al. "Chemical logic of MraY inhibition by antibacterial nucleoside natural products." Nature communications 10.1 (2019): 1-12.

• This paper mentioned MraYAA sdAbs were raised by phage display technology using immunized llama as a repertoire source in partnership with Creative Biolabs.

Apart from our Custom sdAb Production and Manufacture service, Creative Biolabs also provides a variety of recombinant sdAb products of your choice, which can be used directly for research and experimentation purpose.

• Chatterjee, Shilpak, et al. "CD38-NAD+ axis regulates immunotherapeutic anti-tumor T cell response." Cell metabolism 27.1 (2018): 85-100.

• This paper mentioned anti-CD38 V_HH single domain antibody is available at Creative Biolabs.

All services are provided for research purposes only. Our services cannot be used for clinical or therapeutic applications.